Preventable Vaccines - Global Strategic Business Report

The global market for Preventable Vaccines was estimated at US$85.6 Billion in 2023, and is projected to reach US$92.9 Billion by 2030, growing at a CAGR of 1.2% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the preventable vaccines market is driven by several factors, including technological advancements in vaccine development, an increase in government and private funding for immunization programs, and a heightened awareness of the importance of vaccinations. Technological innovations have led to more effective and safer vaccines, with developments in adjuvants and delivery systems improving the immune response and reducing side effects. The global expansion of routine immunization programs, supported by international health organizations and governments, has increased the demand for vaccines, especially in underdeveloped and developing regions. Additionally, consumer behavior has shifted significantly in recent years, with a growing preference for preventive healthcare measures, further spurred by the COVID-19 pandemic’s demonstration of the critical role of vaccinations in controlling infectious diseases. The market`s expansion is also facilitated by the rise in travel and migration, which increases the exposure to different pathogens, thereby boosting the need for broader immunization coverage. This dynamic market is expected to continue growing as new vaccine technologies and international health initiatives expand to meet the challenges of existing and emerging infectious diseases.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Live / Attenuated Vaccines segment, which is expected to reach US$34.1 Billion by 2030 with a CAGR of a 1.3%. The Inactivated Vaccines segment is also set to grow at 1.6% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $23.3 Billion in 2023, and China, forecasted to grow at an impressive 2.1% CAGR to reach $16.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Preventable Vaccines Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Preventable Vaccines Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Preventable Vaccines Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of major players such as AstraZeneca PLC, Bharat Biotech International Ltd., Boehringer Ingelheim International GmbH, and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 86 Featured):

• AstraZeneca PLC
• Bharat Biotech International Ltd.
• Boehringer Ingelheim International GmbH
• Daiichi Sankyo Co., Ltd.
• Emergent BioSolutions, Inc.
• GSK Plc
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Novartis AG
• Novavax, Inc.
• Pfizer, Inc.
• Roche CustomBiotech
• Sanofi SA
• Serum Institute of India Pvt., Ltd.
• Takeda Pharmaceutical Co., Ltd.;